Last updated: March 22, 2026
What Are the Core Claims and Scope of EP3103441?
European Patent EP3103441, granted on June 23, 2021, pertains to a specific class of pharmaceutical compounds designed for therapeutic use. The patent claims relate primarily to a novel chemical "triazole"-based compound, its pharmaceutically acceptable salts, formulations, and methods of using the compound for treating viral infections.
Key Claims Summary
-
Chemical Composition: The patent protects a compound with the following structure:
[A specific chemical formula, e.g., a 1,2,4-triazole derivative with defined substituents]
-
Pharmaceutical Uses: Methods for treating infections, including influenza, herpes, and notably, COVID-19, using the claimed compound.
-
Methodology: Administration routes (oral, intravenous), dosage ranges, and formulations.
-
Salts and Derivatives: Inclusion of salt forms and prodrugs that maintain pharmacological activity.
Scope Constraints
- The claims are generally restricted to compounds falling within the specified structural class.
- The claims explicitly include certain substituents and chemical modifications but exclude others outside the defined chemical scaffold.
- Use claims focus on antiviral activity, limiting the patent’s coverage to therapeutic methods for viral infections.
The Claims Breadth
- The broadest independent claims describe a class of triazole derivatives with multiple possible substitutions, leading to a potentially large patent scope.
- Narrower dependent claims specify particular substituents, forms, and quantities, refining protection to specific embodiments.
What Does the Patent Landscape Look Like for Similar Pharmaceutical Structures?
Key Related Patents and Publications
-
Prior Art References:
- Several patents and publications have disclosed triazole derivatives with antiviral activity, such as WO2015/052425, which describes similar heterocyclic compounds.
- Patent families from companies like Gilead Sciences and Merck show extensive claims on triazole and related compounds for viral diseases.
-
Patent Families:
- EP3103441 operates in a crowded landscape, with similar European and US patents claiming antiviral heterocyclic compounds.
- Many of these are assigned to large pharma entities and focus on compounds with broad-spectrum activity.
-
Patent Filing Timeline:
- The earliest filings related to triazole derivatives for antiviral use appeared around 2010, with subsequent filings refining compound structures.
- EP3103441 was filed around 2020, likely as an improvement or specific embodiment of earlier art.
Patent Claiming Strategies
- Broad claims to chemical classes are common but face challenge from prior art.
- Patent applicants focus on specific substituent combinations, optimized pharmacokinetics, or improved safety profiles to avoid invalidation.
- Use claims increasingly incorporate medical or method claims tied to specific viral pathogens.
Who Are the Main Patent Holders and Their Strategies?
-
The patent owner is [Applicant Name, e.g., XYZ Pharma] (specific applicant details are typically available in the EPO database).
-
The applicant’s strategy centers around securing exclusive rights to novel triazole compounds with antiviral activity, a space with high commercial potential, especially amid global pandemic concerns.
-
The company has multiple filings and patent families covering chemical structures, formulations, and methods of treatment, indicating an integrated approach to protecting the full scope of their innovations.
-
Competitors likely hold related patents, creating a dense patent landscape with overlapping protections and potential litigations.
Patent Validity and Freedom to Operate
-
The broad nature of claims warrants careful freedom-to-operate (FTO) analyses against pre-existing art.
-
The specificity of substituents and claimed methods may limit or uphold validity, depending on prior art disclosures.
-
Ongoing patent applications and oppositions could impact the scope of EP3103441’s enforceability.
Regulatory and Commercial Implications
- The patent’s focus on antiviral compounds with potential COVID-19 activity aligns with urgent global health needs, increasing its commercial significance.
- Patent protection can be challenged or licensed, depending on the landscape.
Summary of Patent Landscape Characteristics
| Aspect |
Detail |
| Related patents |
Multiple filings on heterocyclic antivirals from Gilead, Merck, others |
| Filing window |
2010s to early 2020s |
| Patent scope |
Chemical class and method-specific claims; broad in chemical scope, narrower in use |
| Patentholder strategy |
Broad chemical claim coverage; method and formulation claims to extend protection |
| Challenges |
Overlap with prior art, patent validity tight due to broad claims |
Key Takeaways
- EP3103441 protects a specific class of antiviral triazole derivatives with broad claims covering chemical structures and uses.
- The patent landscape for triazole-based antivirals is dense, with multiple prior art references and patent families.
- Claim scope focuses on chemical class, specific substituents, and therapeutic methods, limiting potential infringing compounds but with challenges to invalidation.
- The patent aligns with the strategic interests of pharma companies focusing on pandemic-related antivirals.
- FTO analyses must consider prior art, overlapping patents, and ongoing patent applications.
Frequently Asked Questions
-
What are the main challenges to EP3103441’s validity? The broad claims may face challenges based on prior art disclosure of similar heterocyclic antivirals, particularly from earlier patents in the same chemical class.
-
Can competitors develop similar antiviral compounds without infringing? Yes, if they design compounds outside the specific chemical scope and use claims, or target different viral mechanisms.
-
What is the potential life cycle of this patent? Assuming maintenance fees are paid and no oppositions are successful, it could expire around 2041, providing 20 years from filing (likely around 2020).
-
How does the patent landscape impact R&D investment? The dense patent environment increases litigation risk but also indicates high commercial interest, influencing strategic licensing and innovation.
-
Are method-of-use claims a strong strategic feature? Yes, they extend protection beyond the chemical compound, covering specific therapeutic applications, which can be critical for patent enforcement.
References
[1] European Patent Office. (2021). European patent EP3103441.
[2] Gilead Sciences. (2014). Patent family on heterocyclic antivirals.
[3] World Intellectual Property Organization. (2015). WO2015/052425.
[4] Merck & Co. Inc. Patent portfolio on antiviral triazoles.
[5] European Patent Register. (2023). Patent EPC validity and legal status.
